IL160170D0 - A host cell engineered to produce a polypeptide having increased cytotoxicity - Google Patents

A host cell engineered to produce a polypeptide having increased cytotoxicity

Info

Publication number
IL160170D0
IL160170D0 IL16017002A IL16017002A IL160170D0 IL 160170 D0 IL160170 D0 IL 160170D0 IL 16017002 A IL16017002 A IL 16017002A IL 16017002 A IL16017002 A IL 16017002A IL 160170 D0 IL160170 D0 IL 160170D0
Authority
IL
Israel
Prior art keywords
polypeptide
produce
host cell
cell engineered
increased cytotoxicity
Prior art date
Application number
IL16017002A
Original Assignee
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30951601P priority Critical
Application filed by Glycart Biotechnology Ag filed Critical Glycart Biotechnology Ag
Priority to PCT/US2002/024739 priority patent/WO2003011878A2/en
Publication of IL160170D0 publication Critical patent/IL160170D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038Kidney, bladder
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals
    • Y02P20/52Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals using catalysts, e.g. selective catalysts

Abstract

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
IL16017002A 2001-08-03 2002-08-05 A host cell engineered to produce a polypeptide having increased cytotoxicity IL160170D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US30951601P true 2001-08-03 2001-08-03
PCT/US2002/024739 WO2003011878A2 (en) 2001-08-03 2002-08-05 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Publications (1)

Publication Number Publication Date
IL160170D0 true IL160170D0 (en) 2004-07-25

Family

ID=23198536

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16017002A IL160170D0 (en) 2001-08-03 2002-08-05 A host cell engineered to produce a polypeptide having increased cytotoxicity
IL160170A IL160170A (en) 2001-08-03 2004-02-02 Host cell engineered to produce a polypeptide having increased cytotoxicity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160170A IL160170A (en) 2001-08-03 2004-02-02 Host cell engineered to produce a polypeptide having increased cytotoxicity

Country Status (15)

Country Link
US (5) US20030175884A1 (en)
EP (2) EP2180044A1 (en)
JP (2) JP2005524379A (en)
KR (2) KR20040054669A (en)
CN (1) CN1555411A (en)
AU (1) AU2002339845B2 (en)
CA (2) CA2455365C (en)
HU (1) HU0700103A3 (en)
IL (2) IL160170D0 (en)
MX (1) MXPA04001072A (en)
NO (1) NO332457B1 (en)
NZ (5) NZ592087A (en)
PL (1) PL217751B1 (en)
RU (1) RU2321630C2 (en)
WO (1) WO2003011878A2 (en)

Families Citing this family (546)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1137789B1 (en) 1998-12-09 2010-07-28 Phyton Holdings, LLC A method for manufacturing glycoproteins having human-type glycosylation
CA2362204C (en) 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
ES2288882T3 (en) 1999-10-26 2008-02-01 Plant Research International B.V. Glammosilation of mammer type in plants.
US7416726B2 (en) * 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
DE60114830T2 (en) * 2000-06-28 2006-08-03 Glycofi, Inc. Process for producing modified glycoproteins
ZA200306406B (en) 2001-01-19 2004-09-06 Dow Chemical Co Method for secretory production of glycoprotein having human-type sugar chain using plant cell.
CA2442801A1 (en) * 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
PL217751B1 (en) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2471092A1 (en) * 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
AU2003219418B2 (en) 2002-03-19 2008-02-28 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
NZ534881A (en) 2002-03-19 2006-09-29 Plant Res Internat B Mammalian GnTIII expression in plants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc Fc varieties with optimized fc receptor binding properties
CL2003002461A1 (en) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Immunoglobulin comprising at least one afucosilado the glycan composition that contains nucleotide sequence and the vector comprising, process for producing said immunoglobulin in plants.
AU2004207233C1 (en) * 2003-01-24 2008-04-24 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 binding molecules
PT1692182E (en) * 2003-11-05 2010-05-13 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
AR048098A1 (en) * 2004-03-15 2006-03-29 Wyeth Corp Calicheamicin conjugates
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20060002930A1 (en) * 2004-04-16 2006-01-05 Genentech, Inc. Treatment of disorders
CN106075435A (en) 2004-06-04 2016-11-09 健泰科生物技术公司 For the method treating multiple sclerosis
AT486610T (en) * 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd ANTI-glypican-3 ANTIBODY
WO2006005367A1 (en) * 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
CN101087807A (en) 2004-10-05 2007-12-12 健泰科生物技术公司 Method for treating vasculitis
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
NZ554940A (en) * 2004-10-26 2010-04-30 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody having modified sugar chain
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
LT1871805T (en) 2005-02-07 2019-12-10 Roche Glycart Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP1848745B1 (en) * 2005-02-18 2014-07-09 Medarex, L.L.C. Monoclonal antibodies against cd30 lacking in fucosyl residues
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
RU2007139283A (en) * 2005-03-25 2009-04-27 Гликарт Биотехнологи Аг (Ch) ANTI-BINDING MOLECULES DIRECTED TO MCSP AND HAVING AN INCREASED BINDING OF Fc-RECEPTOR AND EFFECTOR FUNCTION
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
CN101228189A (en) * 2005-05-09 2008-07-23 格黎卡特生物技术股份公司 Antigen binding molecules having modified FC regions and altered binding to FC receptors
JP2008541758A (en) * 2005-06-02 2008-11-27 アストラゼネカ エービー Antibodies against CD20 and uses thereof
WO2006133148A2 (en) * 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
US9580506B2 (en) 2005-07-21 2017-02-28 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
CA2619825A1 (en) * 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
RU2482132C2 (en) * 2005-08-26 2013-05-20 Роше Гликарт Аг Modified antigen-binding molecules with changed cell signal activity
EP1951757B1 (en) * 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US9102739B2 (en) * 2005-10-14 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
BRPI0619118A2 (en) 2005-12-02 2011-09-13 Genentech Inc compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
PT2548577T (en) 2005-12-29 2017-05-29 Janssen Biotech Inc Human anti-il-23 antibodies, compositions, methods and uses
TWI596111B (en) 2006-01-05 2017-08-21 建南德克公司 Anti-ephb4 antibodies and methods using same
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
WO2008029281A2 (en) * 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc Egfl7 antibodies and methods of use
ES2363891T3 (en) 2006-03-20 2011-08-18 The Regents Of The University Of California Antibodies against the antigen of troncal cells of the prostate (psca) genetically modified for addressing to cancer.
RU2436796C9 (en) 2006-05-30 2013-12-27 Дженентек, Инк. Antibodies and immunoconjugates and their application
BRPI0710413A2 (en) 2006-06-06 2011-08-23 Genentech Inc anti-dll4 antibodies, isolated, polynucleotide, vector, host cell, method for producing an anti-dll4 antibody, method for producing an anti-dll4 immunoconjugate, method for detecting dll4, method for diagnosing a disorder, compositions, method to treat a tumor, cancer and / or cell proliferation disorder and method for enhancing the effectiveness of an anti-angiogenic agent
TWI551607B (en) 2006-07-14 2016-10-01 Ac免疫公司 Humanized antibody
SI2046833T1 (en) 2006-07-14 2013-12-31 Ac Immune S.A. Humanized antibody against amyloid beta
EP2046809B1 (en) 2006-07-19 2016-12-07 The Trustees Of The University Of Pennsylvania Wsx-1/il-27 as a target for anti-inflammatory responses
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Adhesion molecule antigen that attach to EGFR, vectors encoding, and uses of these
RS52775B (en) 2006-08-14 2013-10-31 Xencor Inc. Optimized antibodies that target cd19
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
AU2007324135B2 (en) 2006-10-12 2013-06-27 Genentech, Inc. Antibodies to lymphotoxin-alpha
PT2061814E (en) 2006-10-27 2012-09-10 Genentech Inc Antibodies and immunoconjugates and uses therefor
ES2678060T3 (en) * 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Antibodies, in particular, human antibodies, which bind to CD22 and uses thereof
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
AU2008227024A1 (en) * 2007-03-07 2008-09-18 Glycofi, Inc. Production of glycoproteins with modified fucosylation
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
KR101426576B1 (en) 2007-04-17 2014-08-07 스티칭 디엔스트 랜드보위쿤디그 온데조에크 Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
EP3072525B1 (en) 2007-05-14 2018-01-31 AstraZeneca AB Methods of reducing basophil levels
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
PL2170389T3 (en) 2007-06-12 2015-03-31 Ac Immune Sa Humanized antibodies to amyloid beta
PL2155880T3 (en) * 2007-06-15 2017-06-30 Medicago Inc. Modifying glycoprotein production in plants
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
DE17196350T1 (en) 2007-07-09 2018-12-27 Genentech, Inc. Preventing disulfide binding reduction during the recombinant preparation of polypeptides
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2205632B1 (en) 2007-10-05 2016-11-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
AR069501A1 (en) 2007-11-30 2010-01-27 Genentech Inc Anti- VEGF (vascular endothelial growth factor)
CA2707791A1 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
BRPI0821449A2 (en) 2007-12-26 2015-06-16 Biotest Ag Immunoconjugate, methods for treating multiple myeloma in an individual, for dispensing immunoconjugate-mediated drug, for inhibiting, delaying and / or preventing tumor development and / or dispensing malignant tumor cells in a patient in need thereof, for treating an individual having a condition and to decrease the amount of cells in direct or indirect contact with immunoconjugates, a method for treating multiple myeloma in an individual, to dispense immunoconjugate-mediated medication, to inhibit, delay and / or prevent tumor cell development in a cell culture, to inhibit, delay and / or prevent the development of a tumor and / or dispense malignant tumor cells in a patient in need thereof, to treat an individual having a condition and to decrease a number of cells in direct or indirect contact. with tumor cells, pharmaceutical composition, and kit.
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
ES2543201T3 (en) * 2007-12-26 2015-08-17 Biotest Ag Methods and agents that improve the direction to tumor cells expressing CD138
PL2238168T3 (en) * 2007-12-26 2014-11-28 Biotest Ag Agents targeting cd138 and uses thereof
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
WO2009134738A1 (en) * 2008-04-29 2009-11-05 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
KR101054362B1 (en) * 2008-07-03 2011-08-05 재단법인 목암생명공학연구소 How to reduce the fucose content of recombinant protein
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc Methods for treating progressive multiple sclerosis. An article of manufacture.
WO2010036443A1 (en) * 2008-09-26 2010-04-01 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
BRPI0914091A2 (en) 2008-10-14 2016-09-27 Genentech Inc "igg variant, pharmaceutical composition, kit, method for tumor treatment, method for inhibiting vegf activity, method for modulating vascular permeability, and method for inhibiting or preventing cancer cell growth"
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
EP2350127B1 (en) 2008-10-20 2015-01-28 AbbVie Inc. Isolation and purification of antibodies using protein a affinity chromatography
SI2361085T2 (en) 2008-11-22 2018-11-30 F. Hoffmann-La Roche Ag Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
AR074777A1 (en) 2008-12-19 2011-02-09 Glaxo Group Ltd Antigen-binding proteins
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BRPI0918204A2 (en) 2008-12-23 2015-12-08 Genentech Inc IGV VARIANT PHARMACEUTICAL COMPOSITION and KIT
WO2010098865A1 (en) * 2009-02-26 2010-09-02 Gt Life Sciences, Inc. Mammalian cell line models and related methods
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102378767B (en) 2009-03-25 2015-01-14 健泰科生物技术公司 Anti-fgfr3 antibodies and methods using same
US8124740B2 (en) 2009-03-25 2012-02-28 Genentech, Inc. Anti- α5 β1 antibodies and uses thereof
CN102573916B (en) * 2009-05-06 2017-05-17 生物测试股份公司 Uses of immunoconjugates targeting cd138
WO2010138184A2 (en) 2009-05-27 2010-12-02 Synageva Biopharma Corp. Avian derived antibodies
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
AR077595A1 (en) 2009-07-27 2011-09-07 Genentech Inc Combination treatments
MX2012001306A (en) 2009-07-31 2012-02-28 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists.
KR101822205B1 (en) 2009-08-11 2018-01-25 제넨테크, 인크. Production of proteins in glutamine-free cell culture media
AU2010284446A1 (en) 2009-08-15 2012-03-08 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
TWI412375B (en) * 2009-08-28 2013-10-21 Roche Glycart Ag Humanized anti-cdcp1 antibodies
AU2010288469A1 (en) 2009-08-31 2012-03-01 Roche Glycart Ag Affinity-matured humanized anti CEA monoclonal antibodies
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
MX2012004647A (en) 2009-10-22 2012-06-19 Genentech Inc Anti-hepsin antibodies and methods using same.
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
CN102933600B (en) 2009-11-05 2015-11-25 弗·哈夫曼-拉罗切有限公司 The method and composition of secretion of heterologous polypeptides
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN102753194B (en) 2009-12-02 2015-07-08 伊麦吉纳博公司 J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma)
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
SG181905A1 (en) 2009-12-23 2012-07-30 Genentech Inc Anti-bv8 antibodies and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
PE20170687A1 (en) 2010-01-28 2017-06-13 Glaxo Group Ltd CD127 binding proteins
CA2788758A1 (en) 2010-02-09 2011-08-18 Andrew Ian Bayliffe Treatment of a metabolic disorder
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
BR112012017405A2 (en) 2010-02-18 2018-08-14 Genentech Inc method to increase tumor recurrence time in cancer patient
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
JP2013520442A (en) 2010-02-23 2013-06-06 ジェネンテック, インコーポレイテッド Anti-angiogenic treatment for the treatment of ovarian cancer
PL3025729T3 (en) 2010-03-03 2019-02-28 Glaxo Group Limited Antigen binding proteins specific for serum amyloid p component
SG184033A1 (en) 2010-03-24 2012-10-30 Genentech Inc Anti-lrp6 antibodies
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
DK2975409T3 (en) 2010-05-10 2018-12-17 Acad Sinica Zanamivir phosphonate congeners with anti-influenza activity and determination of oseltamivir sensitivity in influenza viruses
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
CN103119442A (en) 2010-06-03 2013-05-22 霍夫曼-拉罗奇有限公司 Immuno-PEG imaging of antibodies and immunoconjugates and uses therefor
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
AR082017A1 (en) 2010-06-18 2012-11-07 Genentech Inc Anti-axl (receptor tyrosine kinases) and methods of use
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
EP2591004A1 (en) 2010-07-09 2013-05-15 F.Hoffmann-La Roche Ag Anti-neuropilin antibodies and methods of use
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409989A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
JP2013538191A (en) 2010-07-23 2013-10-10 トラスティーズ オブ ボストン ユニバーシティ Anti-DEsupR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
EP2600895A1 (en) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
MX2013001305A (en) 2010-08-05 2013-03-20 Hoffmann La Roche Anti-mhc antibody anti-viral cytokine fusion protein.
US9011847B2 (en) 2010-08-13 2015-04-21 Roche Glycart, AG Anti-FAP antibodies and methods of use
RU2584597C2 (en) 2010-08-13 2016-05-20 Рош Гликарт Аг Antibodies against a2 tenastin-c and methods for use thereof
TW201215405A (en) 2010-08-25 2012-04-16 Hoffmann La Roche Antibodies against IL-18R1 and uses thereof
RU2013114360A (en) 2010-08-31 2014-10-10 Дженентек, Инк. Biomarkers and treatment methods
EP2625197B1 (en) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened and methods of using the same
RU2013126477A (en) 2010-11-08 2014-12-20 Дженентек, Инк. Integrated scan antibodies against il-6 receptor
SG190682A1 (en) 2010-11-10 2013-07-31 Genentech Inc Methods and compositions for neural disease immunotherapy
EP3211009A1 (en) 2010-11-23 2017-08-30 Glaxo Group Limited Antigen binding proteins to oncostatin m (osm)
SG190362A1 (en) 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
PL2646470T3 (en) 2010-11-30 2017-07-31 F.Hoffmann-La Roche Ag Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
AR084342A1 (en) 2010-12-16 2013-05-08 Genentech Inc Diagnosis and treatments related to inhibition of Th2
PE20141114A1 (en) 2010-12-20 2014-09-15 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
MX2013007168A (en) 2010-12-22 2013-11-04 Genentech Inc Anti-pcsk9 antibodies and methods of use.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2482074A1 (en) * 2011-01-27 2012-08-01 Medizinische Hochschule Hannover Methods and means for diagnosing vasculitis
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
CN103476433A (en) 2011-02-10 2013-12-25 罗切格利卡特公司 Improved immunotherapy
MX347590B (en) 2011-03-02 2017-05-03 Roche Glycart Ag Cea antibodies.
BR112013024717A2 (en) 2011-04-07 2017-08-08 Genentech Inc isolated antibody, isolated nucleic acid, host cell, immunoconjugate, pharmaceutical formulation, method of treating an individual who has cancer and method of inhibiting cell proliferation in an individual
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг Immunoconjugates containing interleukin-2 mutant polypetips
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 Utilize framework signature peptide to detect the multiple reaction monitoring LC-MS/MS method of the therapeutic antibodies in animal sample
NZ616206A (en) 2011-05-16 2015-04-24 Genentech Inc Fgfr1 agonists and methods of use
MY166974A (en) 2011-06-15 2018-07-27 Hoffmann La Roche Anti-human epo receptor antibodies and method of use
AR086982A1 (en) 2011-06-22 2014-02-05 Hoffmann La Roche Elimination of target cells by specific cytotoxic T cells using virus complexes comprising MHC class I
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CA2842099A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
CN103890007A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Neuregulin antibodies and uses thereof
US9309306B2 (en) 2011-08-23 2016-04-12 Roche Glycart Ag Anti-MCSP antibodies
JP5925893B2 (en) 2011-08-23 2016-05-25 ロシュ グリクアート アーゲー Bispecific antigen binding molecule
RU2014109395A (en) 2011-09-15 2015-10-20 Дженентек, Инк. Ways to stimulate differentiation
MX2014002990A (en) 2011-09-19 2014-05-21 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists.
BR112014008212A2 (en) 2011-10-05 2017-06-13 Genentech Inc method for treating a liver condition, hepatic differentiation induction method, and abnormal bile duct proliferation reduction method
MX2014004022A (en) 2011-10-14 2014-04-30 Genentech Inc ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
EP2768845B1 (en) 2011-10-19 2017-01-18 Roche Glycart AG Separation method for fucosylated antibodies
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
JP6251682B2 (en) 2011-10-28 2017-12-20 ジェネンテック, インコーポレイテッド Combinations and methods of treatment for melanoma treatment
TW201326193A (en) 2011-11-21 2013-07-01 Genentech Inc Purification of anti-c-met antibodies
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
EP2788030B1 (en) 2011-12-08 2018-06-20 Biotest AG Uses of immunoconjugates targeting cd138
MX355624B (en) 2011-12-22 2018-04-25 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides.
JP2015503907A (en) 2011-12-22 2015-02-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Full-length antibody display system for eukaryotic cells and use thereof
SG10201601882PA (en) 2011-12-22 2016-04-28 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
AU2013208007A1 (en) 2012-01-09 2014-07-31 The Scripps Research Institute Humanized antibodies with ultralong CDR3
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2804630B1 (en) 2012-01-18 2017-10-18 F.Hoffmann-La Roche Ag Methods of using fgf19 modulators
AR089752A1 (en) 2012-01-18 2014-09-17 Genentech Inc Anti-LRP5 and methods of use
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
CA2862316A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
CA2860600A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
RU2014138586A (en) 2012-03-02 2016-04-20 Рош Гликарт Аг Prognostic biomarker for treating cancer with antibodies with an increased antibody-dependent cell cytotoxicity
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc Antibodies and immunoconjugates LGR5
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
AR090903A1 (en) 2012-05-01 2014-12-17 Genentech Inc Antibodies and immunoconjugates anti-PMEL17
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
PL2849723T3 (en) 2012-05-18 2018-10-31 Genentech, Inc. High-concentration monoclonal antibody formulations
CN104520325A (en) 2012-05-21 2015-04-15 霍夫曼-拉罗奇有限公司 Methods for improving safety of blood-brain barrier transport
EP2852610B1 (en) 2012-05-23 2018-07-11 Glykos Finland Oy Production of fucosylated glycoproteins
JP6294311B2 (en) 2012-05-23 2018-03-14 ジェネンテック, インコーポレイテッド How to select a treatment
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CN103463633B (en) * 2012-06-07 2016-03-30 复旦大学 Chimeric hepatitis B virus core antigen therapeutic vaccine of a kind of targeting and uses thereof
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
MX353951B (en) 2012-07-04 2018-02-07 Hoffmann La Roche Anti-theophylline antibodies and methods of use.
PL2869848T3 (en) 2012-07-04 2017-04-28 F.Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
CN104411725B (en) 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 Anti-biotin antibodies and application method
MX356162B (en) 2012-07-05 2018-05-16 Genentech Inc Expression and secretion system.
TW201406785A (en) 2012-07-09 2014-02-16 Genentech Inc Anti-CD22 antibodies and immunoconjugates
KR20150030753A (en) 2012-07-09 2015-03-20 제넨테크, 인크. Immunoconjugates comprising anti-cd79b antibodies
AU2013288931A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti-CD22 antibodies
KR20150030698A (en) 2012-07-09 2015-03-20 제넨테크, 인크. Immunoconjugates comprising anti-cd79b antibodies
NZ702201A (en) 2012-07-13 2018-01-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
ES2673847T3 (en) 2012-07-25 2018-06-26 Celldex Therapeutics, Inc. Anti KIT antibodies and uses thereof
SG10201800535XA (en) 2012-08-07 2018-02-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
JP6211084B2 (en) 2012-08-21 2017-10-11 アカデミア シニカAcademia Sinica Benzocyclooctyne compounds and uses thereof
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
SG11201500583PA (en) 2012-08-29 2015-04-29 Hoffmann La Roche Blood brain barrier shuttle
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
MX2015005757A (en) 2012-11-08 2015-11-18 Hoffmann La Roche Her3 antigen binding proteins binding to the beta-hairpin of her3.
AR093446A1 (en) 2012-11-13 2015-06-10 Genentech Inc Antihaemagglutinin antibodies and methods of use
MX361076B (en) 2012-12-21 2018-11-27 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins.
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
KR20160002713A (en) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20150118159A (en) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 Methods of treating cancer and preventing drug resistance
MX2015010789A (en) 2013-02-26 2015-11-26 Roche Glycart Ag Anti-mcsp antibodies.
EP2964260A2 (en) 2013-03-06 2016-01-13 F.Hoffmann-La Roche Ag Methods of treating and preventing cancer drug resistance
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2970474B1 (en) 2013-03-14 2017-12-20 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
CN105307683A (en) 2013-03-14 2016-02-03 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
LT2970422T (en) 2013-03-15 2018-06-25 F. Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2014235453A1 (en) 2013-03-15 2015-10-08 Genentech, Inc. Biomarkers and methods of treating PD-1 and PD-L1 related conditions
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
BR112015023262A2 (en) 2013-03-15 2017-11-21 Ac Immune Sa isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation and uses of the antibody
TW201522374A (en) 2013-03-15 2015-06-16 Genentech Inc Anti-CRTh2 antibodies and methods of use
BR112015023203A8 (en) 2013-03-15 2018-01-23 Constellation Pharmaceuticals Inc methods for treating cancer, method for increasing the efficiency of cancer treatment, method for delaying and / or preventing cancer development, method for treating an individual with cancer, method for increasing sensitivity for a cancer therapy agent, method for extending a sensitivity period and method for extending the duration of response to cancer therapy.
EP2970476A1 (en) 2013-03-15 2016-01-20 F.Hoffmann-La Roche Ag Compositions and methods for diagnosis and treatment of hepatic cancers
MA38554A3 (en) 2013-04-03 2018-12-31 Roche Glycart Ag Bispecific antibodies directed against paf and DR5 specific antibody against DR5 and methods of use thereof
CN105164158A (en) 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 Fcrn-binding abolished ANTI-IGF-1R antibodies and their use in the treatment of vascular eye diseases
KR20160002858A (en) 2013-04-29 2016-01-08 에프. 호프만-라 로슈 아게 Human fcrn-binding modified antibodies and methods of use
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US20160159928A1 (en) 2013-07-18 2016-06-09 Fabrus, Inc. Humanized antibodies with ultralong complementary determining regions
WO2015017600A1 (en) 2013-08-01 2015-02-05 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
AU2014317889A1 (en) 2013-09-06 2016-03-17 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
CA2922889A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015058132A2 (en) 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use
EP3060685B1 (en) 2013-10-23 2019-05-01 F. Hoffmann-La Roche AG Method of predicting the response of an asthma patient to therapy
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016010065A2 (en) 2013-11-21 2017-12-05 Hoffmann La Roche alpha-synuclein antibodies and methods of use
AU2014363944A1 (en) 2013-12-09 2016-06-09 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
KR20160098328A (en) 2013-12-13 2016-08-18 제넨테크, 인크. Anti-cd33 antibodies and immunoconjugates
EP3080611B1 (en) 2013-12-13 2018-11-14 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG10201800250XA (en) 2013-12-17 2018-02-27 Genentech Inc Anti-cd3 antibodies and methods of use
AU2014364587A1 (en) 2013-12-17 2016-06-16 Genentech, Inc. Methods of treating cancers using PD-1 axis binding antagonists and taxanes
CA2933881A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
LT3087095T (en) 2013-12-24 2019-09-10 Argenx Bvba Fcrn antagonists and methods of use
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
KR20160101721A (en) 2014-01-03 2016-08-25 에프. 호프만-라 로슈 아게 Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
BR112016013849A2 (en) 2014-01-03 2017-10-10 Hoffmann La Roche bispecific antihapten / blood-brain barrier receptor conjugates, their uses, and pharmaceutical formulation
EP3092251A1 (en) 2014-01-06 2016-11-16 F. Hoffmann-La Roche AG Monovalent blood brain barrier shuttle modules
CA2931986A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
SG11201605903SA (en) 2014-01-24 2016-08-30 Genentech Inc Methods of using anti-steap1 antibodies and immunoconjugates
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
SG11201606490YA (en) 2014-02-08 2016-09-29 Genentech Inc Methods of treating alzheimer's disease
RU2016136081A3 (en) 2014-02-08 2018-09-28
CN106068277A (en) 2014-02-12 2016-11-02 豪夫迈·罗氏有限公司 Antialiasing albumen 1 antibody and using method
MX2016010729A (en) 2014-02-21 2016-10-26 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof.
JP2017507945A (en) 2014-02-28 2017-03-23 アラコス インコーポレイテッド Methods and compositions for treating Siglec-8 related diseases
US10435694B2 (en) 2014-03-14 2019-10-08 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
CN107002119A (en) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists
JP6562942B2 (en) 2014-03-27 2019-08-28 アカデミア シニカAcademia Sinica Reactive labeled compounds and uses thereof
CA2943262A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Anti-ox40 antibodies and methods of use
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
KR20170003582A (en) 2014-05-22 2017-01-09 제넨테크, 인크. Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (en) 2014-05-23 2017-01-11 제넨테크, 인크. Mit biomarkers and methods using the same
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
EP3149161A4 (en) 2014-05-27 2017-12-27 Academia Sinica Fucosidase from bacteroides and methods using the same
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
JP2017517552A (en) 2014-06-13 2017-06-29 ジェネンテック, インコーポレイテッド Treatment and prevention of anticancer drug resistance
MX2017000363A (en) 2014-07-11 2017-04-27 Genentech Inc Notch pathway inhibition.
KR20170032350A (en) 2014-07-11 2017-03-22 제넨테크, 인크. Anti-pd-l1 antibodies and diagnostic uses thereof
US10513724B2 (en) 2014-07-21 2019-12-24 Glykos Finland Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
KR20190133078A (en) 2014-08-19 2019-11-29 머크 샤프 앤드 돔 코포레이션 Anti-tigit antibodies
TW201625686A (en) 2014-08-28 2016-07-16 奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for CD19
KR20170042802A (en) 2014-09-08 2017-04-19 아카데미아 시니카 HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TW201625689A (en) 2014-09-12 2016-07-16 建南德克公司 Anti-B7-H4 antibodies and immunoconjugates
BR112017004802A2 (en) 2014-09-12 2017-12-12 Genentech Inc anti-cll-1 and immunoconjugate antibodies
WO2016044396A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
SG10201800851XA (en) 2014-09-26 2018-03-28 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP2017536102A (en) 2014-10-16 2017-12-07 ジェネンテック, インコーポレイテッド Anti-alpha-synuclein antibodies and methods of use
EP3215850B1 (en) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Assays for detecting t cell immune subsets and methods of use thereof
WO2016073789A2 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
EP3217787B1 (en) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Animal model for nephropathy and agents for treating the same
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EA201791057A1 (en) 2014-11-14 2017-10-31 Ф. Хоффманн-Ля Рош Аг Antigensbelting molecules containing thermal ligand of tnf families
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107428820A (en) 2014-11-19 2017-12-01 阿克松神经系统科学公司 Humanization tau antibody in Alzheimer's
JP2018505652A (en) 2014-11-19 2018-03-01 ジェネンテック, インコーポレイテッド Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
JP2018503357A (en) 2014-11-19 2018-02-08 ジェネンテック, インコーポレイテッド Anti-transferrin receptor antibody and method of use thereof
CN107108745A (en) 2014-11-19 2017-08-29 基因泰克公司 Anti- BACE1 antibody is used for the purposes of neural disease immunotherapy with it
EP3227336B1 (en) 2014-12-05 2019-07-03 F.Hoffmann-La Roche Ag Anti-cd79b antibodies and methods of use
RU2017120039A (en) 2014-12-10 2019-01-10 Дженентек, Инк. Antibodies to hematoencephalic barrier receptors and methods of application
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
KR20170128234A (en) 2015-01-16 2017-11-22 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies specific for ROR1 and chimeric antigen receptors
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
EP3250927A2 (en) 2015-01-28 2017-12-06 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
JP2018509413A (en) 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー Methods for reducing serum levels of Fc-containing agents using FcRn antagonists
EP3271723A1 (en) 2015-03-16 2018-01-24 H. Hoffnabb-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CA2980005A1 (en) 2015-03-20 2016-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
JP2018510636A (en) 2015-03-23 2018-04-19 バイエル ファーマ アクチエンゲゼルシャフト Anti-CEACAM6 antibody and use thereof
CA2978185A1 (en) 2015-03-23 2016-09-29 Stephen Sazinsky Antibodies to icos
WO2016161390A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
JP2018516549A (en) 2015-04-24 2018-06-28 ジェネンテック, インコーポレイテッド Methods for identifying bacteria containing binding polypeptides
CN107709363A (en) 2015-05-01 2018-02-16 基因泰克公司 Shelter anti-cd 3 antibodies and application method
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
CN108137686A (en) 2015-05-07 2018-06-08 阿吉纳斯公司 Anti- OX40 antibody and its application method
WO2016196298A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
CN107849124A (en) 2015-06-05 2018-03-27 基因泰克公司 Anti- TAU antibody and application method
KR20180011839A (en) 2015-06-08 2018-02-02 제넨테크, 인크. Treatment of Cancer Using Anti-OX40 Antibody
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
JP2018526972A (en) 2015-06-16 2018-09-20 ジェネンテック, インコーポレイテッド Anti-CD3 antibody and method of use
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
TW201712036A (en) 2015-06-16 2017-04-01 建南德克公司 Humanized and affinity matured antibodies to FcRH5 and methods of use
KR20180012859A (en) 2015-06-17 2018-02-06 제넨테크, 인크. Anti-HER2 antibodies and methods of use
MX2017016353A (en) 2015-06-17 2018-05-02 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes.
EP3514174A1 (en) 2015-06-29 2019-07-24 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
JP2018520153A (en) 2015-06-29 2018-07-26 ジェネンテック, インコーポレイテッド Type II anti-CD20 antibody for use in organ transplantation
RU2611685C2 (en) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Humanized monoclonal antibody specific to syndecan-1
EP3341415A1 (en) 2015-08-28 2018-07-04 H. Hoffnabb-La Roche Ag Anti-hypusine antibodies and uses thereof
CA2999369A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
BR112018005931A2 (en) 2015-09-24 2018-10-09 Abvitro Llc hiv antibody compositions and methods of use
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN108391422A (en) 2015-10-02 2018-08-10 豪夫迈·罗氏有限公司 Pyrrolobenzodiazepines * antibody-drug conjugates and application method
AR106189A1 (en) 2015-10-02 2017-12-20 F Hoffmann-La Roche Ag Bispecific antibodies against human Ab AND human transferrin receptor and methods of use
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
BR112018001530A2 (en) 2015-10-02 2018-11-06 Hoffmann La Roche bispecific antibody, polynucleotide, vector, host cell, methods for producing bispecific antibody and tumor cell growth inhibiting and pharmaceutical composition
CN108602887A (en) 2015-10-02 2018-09-28 豪夫迈·罗氏有限公司 To the bispecific antibody of costimulation TNF receptor-specifics
EP3359572A2 (en) 2015-10-06 2018-08-15 H. Hoffnabb-La Roche Ag Method for treating multiple sclerosis
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
AU2016335750A1 (en) 2015-10-07 2018-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
TW201723190A (en) 2015-10-22 2017-07-01 永斯醫療股份有限公司 Gene signatures for determining ICOS expression
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
MX2018005047A (en) 2015-10-29 2018-09-06 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus.
AU2016344665A1 (en) 2015-10-29 2018-04-19 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
TW201730211A (en) 2015-10-30 2017-09-01 建南德克公司 Anti-Factor D antibodies and conjugates
CN108884149A (en) 2015-11-03 2018-11-23 美国政府(由卫生和人类服务部的部长所代表) HIV-1 GP41 neutralizing antibody and application thereof
EP3371217A1 (en) 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Methods of screening for multispecific antibodies
BR112018010410A8 (en) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc method for treating cancer in a subject, composition, and methods of increasing the number of NK cells and increased number of one or more cells positive for PD-L1
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3405489A1 (en) 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
JP2019506161A (en) * 2016-01-27 2019-03-07 メディミューン,エルエルシー Methods for preparing antibodies having a defined glycosylation pattern
JP2019509721A (en) 2016-02-04 2019-04-11 キュリス,インコーポレイテッド Mutant smoothened and method of using the same
WO2017145166A1 (en) * 2016-02-25 2017-08-31 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Composition and method for treating amyotrophic lateral sclerosis
KR20180119632A (en) 2016-02-29 2018-11-02 제넨테크, 인크. Treatment and Diagnosis Methods for Cancer
EP3426693A4 (en) 2016-03-08 2019-11-13 Acad Sinica Methods for modular synthesis of n-glycans and arrays thereof
CN109153719A (en) 2016-03-15 2019-01-04 中外制药株式会社 Use the method for PD-1 axis binding antagonists and resisting GPC 3 antibodies for treating cancer
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
BR112018069776A2 (en) 2016-03-29 2019-02-05 Janssen Biotech Inc psoriasis treatment with increased dosage range of anti-il-12 and / or anti-il-23 antibodies
CA3019509A1 (en) 2016-04-05 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
BR112018069890A2 (en) 2016-05-02 2019-02-05 Hoffmann La Roche target-specific fusion polypeptide, dimeric fusion polypeptide, isolated nucleic acid, isolated nucleic acid pair, host cell, method for producing a fusion polypeptide, immunoconjugate, pharmaceutical formulation, fusion polypeptide and use of the fusion polypeptide
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3455252A1 (en) 2016-05-11 2019-03-20 H. Hoffnabb-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3455254A1 (en) 2016-05-11 2019-03-20 H. Hoffnabb-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2018220099A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3475298A1 (en) 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Anti-polyubiquitin multispecific antibodies
CN109415435A (en) 2016-07-04 2019-03-01 豪夫迈·罗氏有限公司 Novel antibodies form
MX2019001184A (en) 2016-07-29 2019-09-26 Juno Therapeutics Inc Anti-idiotypic antibodies against anti-cd19 antibodies.
MX2018015721A (en) 2016-07-29 2019-05-27 Chugai Pharmaceutical Co Ltd Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity.
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
EP3515932A1 (en) 2016-09-19 2019-07-31 H. Hoffnabb-La Roche Ag Complement factor based affinity chromatography
WO2018057849A1 (en) 2016-09-23 2018-03-29 Genentech, Inc. Uses of il-13 antagonists for treating atopic dermatitis
US20190300618A1 (en) 2016-09-26 2019-10-03 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
US20190225692A1 (en) 2016-10-03 2019-07-25 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
TW201819640A (en) 2016-10-06 2018-06-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
MX2019004834A (en) 2016-11-02 2019-06-20 Jounce Therapeutics Inc Antibodies to pd-1 and uses thereof.
TW201827075A (en) 2016-11-15 2018-08-01 美商建南德克公司 Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CN110248960A (en) 2016-11-19 2019-09-17 波滕扎治疗公司 Anti- GITR antigen-binding proteins and its application method
AU2017361887B2 (en) 2016-11-21 2019-08-15 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
US20180155422A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
MX2019006330A (en) 2016-12-07 2019-09-26 Genentech Inc Anti-tau antibodies and methods of their use.
PE20191135A1 (en) 2016-12-07 2019-09-02 Genentech Inc Antitau antibodies and methods of use
KR20190089949A (en) 2016-12-07 2019-07-31 아게누스 인코포레이티드 Antibodies and methods for their use
CN110366562A (en) 2016-12-12 2019-10-22 豪夫迈·罗氏有限公司 Use the method for anti-PD-L1 antibody and anti-androgen therapy cancer
KR20190097039A (en) 2016-12-19 2019-08-20 에프. 호프만-라 로슈 아게 Combination Therapy with Targeted 4-1BB (CD137) Agonists
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
WO2018119171A1 (en) 2016-12-23 2018-06-28 Potenza Therapeutics, Inc. Anti-neuropilin antigen-binding proteins and methods of use thereof
EP3565843A1 (en) 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US20180230233A1 (en) 2017-02-10 2018-08-16 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
EP3580235A1 (en) 2017-02-10 2019-12-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TW201838649A (en) 2017-03-22 2018-11-01 美商建南德克公司 Optimized antibody compositions for treatment of ocular disorders
WO2018183175A1 (en) 2017-03-28 2018-10-04 Genentech, Inc. Methods of treating neurodegenerative diseases
CN110382542A (en) 2017-03-29 2019-10-25 豪夫迈·罗氏有限公司 For the bispecific antigen binding molecules of costimulation TNF receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110546163A (en) 2017-03-30 2019-12-06 波坦察治疗学股份有限公司 anti-TIGIT antigen binding proteins and methods of use thereof
AU2018247767A1 (en) 2017-04-03 2019-09-19 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
SG11201908787WA (en) 2017-04-04 2019-10-30 Hoffmann La Roche Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
CN110392698A (en) 2017-04-05 2019-10-29 豪夫迈·罗氏有限公司 Anti- LAG3 antibody
TW201839400A (en) 2017-04-14 2018-11-01 美商建南德克公司 Diagnostic and therapeutic methods for cancer
CN110536691A (en) 2017-04-21 2019-12-03 豪夫迈·罗氏有限公司 The purposes of KLK5 antagonist for treating disease
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
TW201908730A (en) 2017-07-21 2019-03-01 美商建南德克公司 The diagnosis and treatment of cancer
US20190119396A1 (en) 2017-07-26 2019-04-25 Forty Seven, Inc. Anti-SIRP-Alpha Antibodies and Related Methods
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019086500A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
WO2019086499A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Novel tnf family ligand trimer-containing antigen binding molecules
WO2019086497A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
TW201923089A (en) 2017-11-06 2019-06-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
CA3025536A1 (en) 2017-12-01 2019-06-01 Pfizer, Inc. Anti-cxcr5 antibodies and compositions and uses thereof
WO2019110823A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
TW201930356A (en) 2017-12-21 2019-08-01 瑞士商赫孚孟拉羅股份公司 Antibodies binding to HLA-A2/WT1
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
US20190194327A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
WO2019129679A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
WO2019134981A1 (en) 2018-01-05 2019-07-11 Ac Immune Sa Misfolded tdp-43 binding molecules
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019148026A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Il-22 fc fusion proteins and methods of use
WO2019148020A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
US20190270814A1 (en) 2018-02-08 2019-09-05 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
TW201936641A (en) 2018-02-09 2019-09-16 瑞士商赫孚孟拉羅股份公司 Antibodies binding to GPRC5D
WO2019158645A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
WO2019165075A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody dosing regimens
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
WO2019165122A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
WO2019175125A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
WO2019178316A1 (en) 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
WO2019191552A1 (en) 2018-03-29 2019-10-03 Genentech, Inc. Modulating lactogenic activity in mammalian cells
WO2019195514A1 (en) 2018-04-04 2019-10-10 Genentech, Inc. Methods for detecting and quantifying fgf21
US20190321401A1 (en) 2018-04-05 2019-10-24 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2019197600A1 (en) 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
WO2019234576A1 (en) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) * 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
KR850004274A (en) * 1983-12-13 1985-07-11 원본미기재 Method of producing erythropoietin
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
AT243713T (en) * 1989-05-25 2003-07-15 Sloan Kettering Inst Cancer Antiidiotypical antibody inducing an immune response to a glycosphingolipid and its use
DE4028800A1 (en) 1990-09-11 1992-03-12 Behringwerke Ag Genetic sialylation of glycoproteins
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
US5753229A (en) * 1991-09-25 1998-05-19 Mordoh; Jose Monoclonal antibodies reactive with tumor proliferating cells
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994016094A2 (en) 1993-01-12 1994-07-21 Biogen, Inc. Recombinant anti-vla4 antibody molecules
WO1995024494A1 (en) 1994-03-09 1995-09-14 Abbott Laboratories Humanized milk
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
JP3606536B2 (en) * 1995-11-17 2005-01-05 タカラバイオ株式会社 Viral replication inhibitor
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888532A (en) 1996-08-16 1999-03-30 Pritsos; Chris A. Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5952203A (en) * 1997-04-11 1999-09-14 The University Of British Columbia Oligosaccharide synthesis using activated glycoside derivative, glycosyl transferase and catalytic amount of nucleotide phosphate
EP2261229A3 (en) * 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020133841A1 (en) 2000-12-11 2002-09-19 Leviten Michael W. Transgenic mice containing huntingtin interacting protein gene disruptions
CA2442801A1 (en) * 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
PL217751B1 (en) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
NZ582315A (en) 2003-01-22 2011-01-28 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
PT1692182E (en) 2003-11-05 2010-05-13 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
LT1871805T (en) 2005-02-07 2019-12-10 Roche Glycart Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
RU2482132C2 (en) 2005-08-26 2013-05-20 Роше Гликарт Аг Modified antigen-binding molecules with changed cell signal activity
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Adhesion molecule antigen that attach to EGFR, vectors encoding, and uses of these
AU2010288469A1 (en) 2009-08-31 2012-03-01 Roche Glycart Ag Affinity-matured humanized anti CEA monoclonal antibodies

Also Published As

Publication number Publication date
NZ603111A (en) 2014-05-30
CA2838062C (en) 2015-12-22
WO2003011878A2 (en) 2003-02-13
KR20040054669A (en) 2004-06-25
CA2455365C (en) 2014-07-29
US20030175884A1 (en) 2003-09-18
HU0700103A2 (en) 2007-05-02
US8021856B2 (en) 2011-09-20
US9631023B2 (en) 2017-04-25
US20150274837A1 (en) 2015-10-01
JP2005524379A (en) 2005-08-18
NZ592087A (en) 2012-11-30
EP1423510A2 (en) 2004-06-02
CN1555411A (en) 2004-12-15
US20050272128A1 (en) 2005-12-08
RU2004106559A (en) 2005-05-10
NZ581474A (en) 2011-04-29
MXPA04001072A (en) 2005-02-17
JP2009114201A (en) 2009-05-28
AU2002339845B2 (en) 2009-03-26
KR20100018071A (en) 2010-02-16
NO20040453L (en) 2004-03-30
CA2455365A1 (en) 2003-02-13
US8999324B2 (en) 2015-04-07
EP2180044A1 (en) 2010-04-28
PL374178A1 (en) 2005-10-03
US9321843B2 (en) 2016-04-26
EP1423510A4 (en) 2005-06-01
IL160170A (en) 2009-05-04
NO332457B1 (en) 2012-09-24
WO2003011878A3 (en) 2003-11-06
CA2838062A1 (en) 2003-02-13
NZ571596A (en) 2010-11-26
NZ531219A (en) 2007-07-27
US20080280322A9 (en) 2008-11-13
HU0700103A3 (en) 2012-09-28
US20160272719A1 (en) 2016-09-22
RU2321630C2 (en) 2008-04-10
US20110293609A1 (en) 2011-12-01
PL217751B1 (en) 2014-08-29

Similar Documents

Publication Publication Date Title
DK1427750T3 (en) Modified transferrin fusion proteins
DE50207501D1 (en) Biologically functional, metabolically inductive implant surfaces
DE60221553D1 (en) Process for the production of recombinant proteins in eukaryontic cells
BR0212023B1 (en) compounds, compositions and method for invertebrate pest control.
WO2002057293B1 (en) Modified zinc finger binding proteins
MXPA03009042A (en) Epitope sequences.
EP1644416A4 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
CA2378871A1 (en) Design of beta-sheet proteins with specific binding properties
CY1108960T1 (en) Antibody blocking cripto AND THEIR USES
IL188094A (en) Il-1?? binding antibodies or fragments thereof and compositions comprising the same
EP1516053A4 (en) Xylanases, nucleic adics encoding them and methods for making and using them
IL161100A (en) Nucleic acid molecules as regulators of developmental timing, recombinant expression vectors comprising the same and compositions comprising them
CA2424602A1 (en) Antibody composition-producing cell
AT514717T (en) Recombinant production of antibody mixtures
WO2004020595A3 (en) Novel human polypeptides encoded by polynucleotides
IL164417D0 (en) Anti-her2 antibody variants
MXPA04003798A (en) Glycoprotein compositions.
MXPA02009896A (en) Chemically modified novel erythropoietin stimulating protein compositions and methods.
UA80427C2 (en) Substituted phenylacetamides and their use as glucokinase activators
CA2524899A1 (en) Generation of artificial binding proteins based on ubiquitin proteins
BR0113112A (en) Antibodies, antidual integrin, compositions, methods and uses
ZA200308706B (en) Quasi-unidirectional fabric for ballistic applications.
EP1462459A4 (en) Process for producing modified polymer, modified polymer obtained by the process, and rubber composition
SI1917276T1 (en) Process for the preparation of glycosylated interferon beta
WO2003046150A3 (en) Glycoprotein remodeling using endoglycanases